drug

(glimepiride + pioglitazone hydrochloride)

Marketedupdated 2mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1m ago

Found something off?

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 30, 2027

207 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jun 8, 2028formulationUS 80711301.9y
Jun 8, 2028formulationUS 80711301.9y
Jan 30, 2027formulationUS 7700128207d
Jan 30, 2027formulationUS 7700128207d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?